The invention relates to a new crystalline form of the methanesulfonic acid addition
salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide
of formula 1, which may be used for example for tumor therapy.